All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
FDA approves extended indication of daunorubicin plus cytarabine to include pediatric patients with AML
By Claire Baker
Bookmark this article
On March 30, 2021, the U.S. Food and Drug Administration (FDA) approved an extended indication for CPX-351 (a liposomal formulation of daunorubicin and cytarabine). This means that the label for CPX-351 has been revised to include the treatment of pediatric patients (aged ≥1 year) with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Two studies—AAML1421 and CPX-MA-1201—highlighted the promising safety profile of the regimen in pediatric patients and formed the basis of the extended approval. Data from both studies, alongside those conducted in adult patients, suggest that the safety and toxicity profile of CPX-351 do not differ between age groups.
Jazz Pharmaceuticals plc. Jazz Pharmaceuticals announces FDA approval of additional indication for Vyzeos (daunorubicin and cytarabine) for the treatment of secondary acute myeloid leukemia in pediatric patients. https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-fda-approval-of-additional-indication-for-vyxeos-daunorubicin-and-cytarabine-for-the-treatment-of-secondary-acute-myeloid-leukemia-in-pediatric-patients-301259059.html. Published March 30, 2021. Accessed March 31, 2021.
Your opinion matters
28 votes - 49 days left ...
Newsletter
Subscribe to get the best content related to AML delivered to your inbox